Jurnalul de Chirurgie
 Jurnalul de chirurgie
Aparitie trimestriala in a doua luna a trimestrului
Published quarterly in the second month of the quarter
ISSN: 1584 - 9341 Vol.10 Nr.3 - Iulie-Septembrie 2014 | luni, 17 iunie 2019
ISSN: 1584 - 9341 Vol.10 No.3 - July-September 2014
English
British Flag| Romana Romanian Flag
 
Creditare EMC
Colegiul Medicilor
Va invitam sa va inregistrati/abonati la Jurnalul de chirurgie pentru a beneficia de creditare EMC
User

Parola

Tine minte
Ti-ai uitat parola?
Syndicate

Advertisement

Elmed

Estima

Liamed

Listare E-mail

HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY WITH CYTOREDUCTIVE SURGERY FOR THE TREATMENT OF PERITONEAL CARCINOMATOSIS FROM COLORECTAL ORGIN
I. Huțanu (1,2), I. Radu (1,2), B. Filip (1,2), Mihaela Buna (2), Maria Gabriela Aniţei (1,2),
M. Deraco (3), V. Scripcariu (1,2)
1) Universitatea de Medicină și Farmacie „Gr.T. Popa” Iași
2) Clinica I Chirurgie Oncologică, Institutul Regional de Oncologie Iași
3) Department of Surgery, Fondazione IRCCS, Istituto Nazionale Tumouri Milano, Milano, Italia; Peritoneal Surface Malignancy Program
Jurnalul de chirurgie (Iaşi) 2013; 9(2): 127-136.
Full text: 
Format PDF (Română/Romanian)

Abstract:

Peritoneal carcinomatosis due to gastrointestinal malignancies has been considered a poor prognosis entity. Few prospective studies have shown 6 to 12 months suvirval period for peritoneal carcinomatosis of colorectal cancer (CR) treated with systemic chemotherapy. New chemotherapeutic agents and monoclonal antibodies increased survival to 16-22 months. Despite this new systemic treatment most patients will die due to cachexia, peritonitis and/or intestinal occlusion. Normothermic or hyperthermic intraperitoneal chemotherapy, intraoperative or early postoperative became in the last three decades the standard treatment for several malignancies of peritoneum and it has proven effective in peritoneal carcinomatosis of colorectal and ovarian origin. The main drawbacks of this method is lack of studies to confirm the benefits. A long learning curve, high morbidity and mortality, lack of studies on quality of life and the high cost of this procedure appears to be the most important disadvantages of this method. Recent studies including carreful selected patients show a five year suvirval rate of 40%, median survirval period of 30 months, high morbidity (up to 60%) and a mortality up to 8%. Phase III trials on patients with peritoneal carcinomatosis from colorectal cancer treated with HlPEC are still ongoing. We present and review the latest results from the literature regarding the value of HIPEC in peritoneal carcinomatosis from colorectal origin.

KEY WORDS: PERITONEAL CARCINOMATOSIS; COLORECTAL CANCER; HYPER-THERMIC INTRAPERITONEAL CHEMOTHERAPY; HIPEC; CYTOREDUCTIVE SURGERY

SHORT TITLE: Chimioterapia hipertermică intraperitoneală (CHIP) în CCR
             Hyperthermic intraperitoneal chemotherapy (HIPEC) in CRC

HOW TO CITE: Huțanu I, Radu I, Filip B, Buna M, Deraco M, Scripcariu V. [Hyperthermic intraperitoneal chemotherapy with cytoreductive surgery for the treatment of peritoneal carcinomatosis from colorectal orgin] Jurnalul de chirurgie (Iaşi). 2013; 9(2): 127-136. DOI: 10.7438/1584-9341-9-2-3.


: Creative Commons License
Jurnalul de chirurgie [Journal of Surgery] by Editorial Board, Department of Surgery University of Medicine and Pharmacy Iasi, E. Tarcoveanu, R. Moldovanu is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Based on a work at www.jurnaluldechirurgie.ro.